Dyax

 

Advancing Novel Biotherapeutics Since 1995®

Press Releases

All Releases
View Summary Dyax Announces Publication of KALBITOR® (ecallantide) EDEMA4® Trial Results in the Annals of Allergy, Asthma, and Immunology
Jun 7, 2010
PDF 24.9 KB Add to Briefcase
View Summary Dyax Corp. to Present at June 2010 Investor Conferences
Jun 2, 2010
PDF 17.2 KB Add to Briefcase
View Summary Dyax Corp. to Present at the Rodman & Renshaw Annual Global Investment Conference
May 10, 2010
PDF 16.9 KB Add to Briefcase
View Summary Dyax Corp. Announces First Quarter 2010 Financial Results
Apr 28, 2010
PDF 73.9 KB Add to Briefcase
View Summary Dyax Corp. to Host First Quarter 2010 Earnings Call and Webcast
Apr 21, 2010
PDF 17.6 KB Add to Briefcase
View Summary Dyax Corp. Sells Rights to Xyntha® Royalty Stream to Paul Capital Healthcare for up to $12 Million
Apr 20, 2010
PDF 22.3 KB Add to Briefcase
View Summary First-Ever Published Study Underscores Significant Economic Burden of Hereditary Angioedema on Patients, Families and the Healthcare System
Apr 5, 2010
PDF 21.6 KB Add to Briefcase
View Summary Dyax Corp. to Present at the 2010 Future Leaders in the Biotech Industry Conference
Apr 5, 2010
PDF 16.9 KB Add to Briefcase
View Summary Dyax Announces Underwriter's Exercise of Over-allotment Option
Apr 5, 2010
PDF 18.5 KB Add to Briefcase
View Summary Dyax Announces Pricing of Public Offering of Common Stock
Mar 25, 2010
PDF 19.5 KB Add to Briefcase
View Summary Dyax Announces Proposed Public Offering of Common Stock
Mar 24, 2010
PDF 19.0 KB Add to Briefcase
View Summary KALBITOR® (ecallantide) Data Presented at American Academy of Allergy, Asthma and Immunology Annual Meeting
Mar 2, 2010
PDF 26.3 KB Add to Briefcase
View Summary Dyax Corp. to Present at the Cowen and Company Health Care Conference
Feb 24, 2010
PDF 16.7 KB Add to Briefcase
View Summary Dyax Corp. Announces Fourth Quarter and Year End 2009 Financial Results
Feb 17, 2010
PDF 78.6 KB Add to Briefcase
View Summary Dyax Corp. to Host Fourth Quarter and Year End 2009 Earnings Call and Webcast
Feb 10, 2010
PDF 17.0 KB Add to Briefcase
View Summary KALBITOR® (ecallantide) Now Commercially Available
Feb 2, 2010
PDF 27.8 KB Add to Briefcase
View Summary Dyax Corp. to Present at the BIO CEO & Investor Conference
Feb 1, 2010
PDF 16.7 KB Add to Briefcase
View Summary Dyax Launches HAE Hope, A New Online Resource for Patients with Hereditary Angioedema
Jan 14, 2010
PDF 19.1 KB Add to Briefcase
View Summary Dyax Announces FDA Approval of KALBITOR® (ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema in Patients 16 Years of Age and Older
Dec 1, 2009
PDF 24.3 KB Add to Briefcase
View Summary DX-88 (ecallantide) Demonstrated Relief of Symptoms in Hereditary Angioedema Acute Attacks in All Attack Locations
Nov 7, 2009
PDF 24.3 KB Add to Briefcase
Showing 121-140 of 203 Page: 1 ... 3 4 5 6 7 8 9 10 11  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase
 

You are now leaving Dyax.com.

The web site you are about to visit is . It is neither owned nor controlled by Dyax Corp. Dyax is not responsible for the content, products or services on this site.

Do you wish to continue?